DrugPatentWatch Database Preview
EXELON Drug Profile
see a sample report or, see our see our flat-rate plans
When do Exelon patents expire, and when can generic versions of Exelon launch?
Exelon is a drug marketed by Novartis and is included in three NDAs. There are two patents protecting this drug and four Paragraph IV challenges.
The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for EXELON
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 3 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 61 |
| Clinical Trials: | 26 |
| Patent Applications: | 4,111 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EXELON |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for EXELON |
| DailyMed Link: | EXELON at DailyMed |
Pharmacology for EXELON
| Drug Class | Cholinesterase Inhibitor |
| Mechanism of Action | Cholinesterase Inhibitors |
Medical Subject Heading (MeSH) Categories for EXELON
Synonyms for EXELON
| (R)-Rivastigmine (Rivastigmine EP Impurity D) |
| (S)-1-(3-((ethyl(methyl)carbamoyl)oxy)phenyl)-N,N-dimethylethanamine |
| (S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate |
| (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate |
| (S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate |
| [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methyl-carbamate |
| [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate |
| [3-[(1S)-1-dimethylaminoethyl]phenyl] N-ethyl-N-methylcarbamate |
| 101R548 |
| 123441-03-2 |
| 2,3-dihydroxybutanedioic acid; 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate |
| 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate |
| 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester |
| 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate |
| 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl N-methyl carbamate |
| 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate |
| 3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate |
| AB01275472_02 |
| AB01275472_03 |
| AB01275472-01 |
| AB1004572 |
| ABP001082 |
| AC-8250 |
| AC1L2U92 |
| AJ-08211 |
| AK161672 |
| AKOS015896334 |
| AN-1074 |
| API0008913 |
| BC225687 |
| BDBM10620 |
| BDBM11682 |
| BIDD:GT0316 |
| C-23825 |
| C11766 |
| Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester |
| Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)- |
| CC-34273 |
| CCG-221197 |
| CHEBI:8874 |
| CHEMBL636 |
| CS-0946 |
| D03822 |
| D0WY5Q |
| DB00989 |
| DR000673 |
| DTXSID7023564 |
| EBD46209 |
| ENA 713 free base |
| ENA-713 |
| Ethyl-methyl-carbamic acid 3-((R)-1-dimethylamino-ethyl)-phenyl ester |
| Ethyl-methyl-carbamic acid 3-((S)-1-dimethylamino-ethyl)-phenyl ester |
| Ethyl-methyl-carbamic acid 3-(1-dimethylamino-ethyl)-phenyl ester |
| Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester |
| Exelon Patch |
| Exelon; Rivastigmine hydrogen tartrate; 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylc |
| F10108 |
| FT-0651952 |
| GTPL6602 |
| HMS2089H18 |
| HY-17368 |
| I06-2037 |
| KS-00000H18 |
| LS-172571 |
| m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate |
| MFCD00871496 |
| MLS003876822 |
| MolPort-003-666-662 |
| NCGC00167531-03 |
| Nimvastid |
| OR210090 |
| PKI06M3IW0 |
| Prometax |
| Prometax (TN) |
| rivastigmine |
| Rivastigmine (JAN/USAN/INN) |
| Rivastigmine (transdermal patch) |
| Rivastigmine [USAN:INN:BAN:JAN] |
| Rivastigmine [USAN:INN] |
| rivastigmine hexal |
| Rivastigmine Teva |
| Rivastigmine Transdermal System |
| Rivastigmine.tartrate |
| RL06150 |
| S-Rivastigmine |
| S4687 |
| SCHEMBL2764 |
| SDZ 212-713 |
| SDZ-212-713 |
| SDZ-ENA-713 |
| SMR002203623 |
| ST24049123 |
| UNII-PKI06M3IW0 |
| W-200966 |
| W-5183 |
| XSVMFMHYUFZWBK-NSHDSACASA-N |
| Y9059 |
| ZINC4413 |
US Patents and Regulatory Information for EXELON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-003 | Apr 21, 2000 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Novartis | EXELON | rivastigmine | FILM, EXTENDED RELEASE;TRANSDERMAL | 022083-002 | Jul 6, 2007 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-006 | Apr 21, 2000 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for EXELON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-003 | Apr 21, 2000 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Novartis | EXELON | rivastigmine tartrate | CAPSULE;ORAL | 020823-005 | Apr 21, 2000 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Novartis | EXELON | rivastigmine tartrate | SOLUTION;ORAL | 021025-001 | Apr 21, 2000 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for EXELON
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Transdermal System Extended-release | 13.3 mg/24 hr | ➤ Subscribe | ➤ Try a Free Trial |
| ➤ Subscribe | Transdermal System Extended-release | 4.6 mg/24 hr and 9.5 mg/24 hr | ➤ Subscribe | ➤ Try a Free Trial |
| ➤ Subscribe | Oral Solution | 2 mg/mL | ➤ Subscribe | ➤ Try a Free Trial |
| ➤ Subscribe | Capsules | 1.5 mg, 3 mg, 4.5 mg and 6 mg | ➤ Subscribe | ➤ Try a Free Trial |
see a sample report or, see our see our flat-rate plans
International Patents for EXELON
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Spain | 2184408 | ➤ Try a Free Trial |
| Czech Republic | 20002557 | ➤ Try a Free Trial |
| Poland | 201328 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for EXELON
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 80031 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512 |
| C0038 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731 |
| C/GB98/041 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
